Final pricing of neratinib/neratinib in 2026

Neratinib/Neratinib (Neratinib) is an oral irreversible pan-HER tyrosine kinase inhibitor with a clear positioning in the extended adjuvant treatment and advanced treatment of HER2-positive breast cancer. As the original version of the drug is officially launched in China, its price and medical insurance policies have become the focus of widespread concern among patients and clinicians. Judging from the current public information, neratinib has been included in Category B management of the National Medical Insurance Directory, but medical insurance payment has strict indication restrictions and is only applicable to HER2-positive breast cancer patients who meet the conditions recommended by the guideline. This is particularly critical in actual reimbursement.

In the domestic market, the common specifications of the original drug of neratinib are40 mg × 180 tablets, which can basically meet the standard dosage for one month. Its official price is around RMB 7,000, which is a relatively controllable range among innovative targeted drugs. After combined with medical insurance policies, the actual out-of-pocket payment ratio of eligible patients can be significantly reduced, which also improves the accessibility of drugs to a certain extent.

In overseas markets, the original drug of neratinib has been in a high price range for a long time, and the price of a single box may exceed US$10,000. This is closely related to the local drug pricing system, R&D cost sharing and insurance structure. Against this background, overseas generic drugs have gradually entered patients' horizons and become an alternative choice for price-sensitive people. Take the generic drug of neratinib produced by Lucius Pharmaceutical Factory in Laos as an example. Its specification is also 40 mg × 180 tablets. It is consistent with the original drug in terms of ingredients and dosage design. The main difference is reflected in the price. Current public channels show that the selling price of this type of generic drugs is about more than 2,000 yuan, and the price advantage is relatively prominent. However, it needs to be emphasized that regulatory standards and quality control systems for generic drugs vary in different countries and regions. Patients should be more cautious when choosing and avoid using price as the only basis for judgment.

Reference materials:https://www.drugs.com/nerlynx.html